Table 1.
Patient characteristics of ETS-unachieved and ETS-achieved groups.
| ETS-unachieved group | P-value | ETS-achieved group | P-value | ||||||
|---|---|---|---|---|---|---|---|---|---|
| All (n = 200) | GC (n = 106) | GS (n = 94) | All (n = 77) | GC (n = 36) | GS (n = 41) | ||||
| Age (years) | Median (range) | 66 (37-79) | 66.5 (45-78) | 66 (37-79) | .67 | 68 (27-78) | 68.5 (52-78) | 68 (27-78) | .93 |
| Sex | Male/female, n (%) | 111/89 (56/45) | 59/47 (56/44) | 52/42 (55/45) | 1.00 | 35/42 (46/55) | 17/19 (47/53) | 18/23 (44/56) | .82 |
| ECOG PS | 0/1, n (%) | 150/50 (75/25) | 80/26 (76/25) | 70/24 (75/26) | .88 | 46/31 (60/40) | 21/15 (58/42) | 25/16 (61/40) | .82 |
| Primary site | Gall bladder, n (%) | 75 (38) | 41 (39) | 34 (36) | 40 (52) | 16 (44) | 24 (59) | ||
| Others, n (%) | 125 (63) | 65 (61) | 60 (64) | .77 | 37 (48) | 20 (56) | 17 (42) | .26 | |
| Primary site | ICC, n (%) | 66 (33) | 34 (32) | 32 (34) | .89 | 21 (28) | 11 (31) | 10 (24) | .47 |
| ECC, n (%) | 47 (24) | 24 (23) | 23 (25) | 16 (21) | 9 (25) | 7 (17) | |||
| Others, n (%) | 87 (44) | 48 (45) | 39 (42) | 40 (52) | 16 (44) | 24 (59) | |||
| Resection | Present, n (%) | 43 (22) | 21 (20) | 22 (23) | .61 | 16 (21) | 9 (25) | 7 (17) | .41 |
| Stage | M1, n (%) | 124 (62) | 66 (62) | 58 (62) | .76 | 51 (66) | 23 (64) | 28 (68) | .74 |
| Diameter of measurable target lesions (mm) | Median (range) | 51.5 (10.0-210.0) | 56.1 (10.0-210.0) | 46.0 (11.0-192.0) | .15 | 52.8 (11.0-184.9) | 45.1 (11.0-184.9) | 60.1 (17.0-180.2) | .04 |
| CEA (ng/mL) | Median (range) | 4.3 (0.8-3706.5) | 3.8 (0.8-3706.5) | 4.6 (0.8-1731.0) | .62 | 3.9 (0.9-2747.8) | 3.0 (0.9-681.4) | 5.3 (1.2-2747.8) | .12 |
| CA19-9 (U/mL) | Median (range) | 175.1 (0.0-1367000.0) | 126.0 (0.9-1367000.0) | 236.0 (0.0-111100.0) | .64 | 170.2 (1.0-76460.0) | 151.6 (1.0-62525.0) | 295.5 (1.0-76460.0) | .13 |
Abbreviations: ETS: early tumor shrinkage; GC: gemcitabine plus cisplatin; GS: gemcitabine plus S-1; ECOG PS: Eastern Cooperative Oncology Group performance status; CEA: serum carcinoembryonic antigen; CA19-9: serum carbohydrate antigen 19-9; ICC: intrahepatic cholangiocarcinoma; ECC: extrahepatic cholangiocarcinoma.